Episode 028: Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
The Filtrate:
Matt Sparks
Joel Topf
Joshua Waitzman
And two special guests:
Anna Burgner, Assistant Professor of Medicine at Vanderbilt University (Twitter)
George Bakris, Professor of Medicine at the University of Chicago (Twitter🔒)
Show Notes:
Bakris’s Phase Two trial of Finerenone in JAMA in 2015: Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
Pharmacokinetics of ACEi and ARB: Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update
Article on supra-maximal doses of ACEi: High-dose ACE inhibition: Can it improve renoprotection?
Bakris looks at risk of hyperkalemia in Seminars in Nephrology: Prediction and management of hyperkalemia across the spectrum of chronic kidney disease
Richard Nixon, “I’m glad you asked me that question…”
Amber trial coverage in NephJC
Article on changes in GFR as an FDA end-point.
Common problems related to the use of number needed to treat
Review of steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. European Heart Journal.
Meta analysis showing the risk of hyperkalemia with aldosterone antagonists: Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis
CREDENCE post-hoc analysis of patients with eGFR < 30: Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m 2: Subgroup Analysis of the Randomized CREDENCE Trial